Corneal Staining Associated With Daily Disposable Beauty Contact Lenses
NCT ID: NCT01882465
Last Updated: 2018-06-19
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
35 participants
INTERVENTIONAL
2013-08-31
2013-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Contact Lenses and Conjunctival Staining in Normal Patients
NCT00799422
Open Eye Corneal Swelling With Daily Disposable Contact Lenses and no Lens Wear
NCT01765972
Evaluation of Corneal Staining With Various Contact Lens/Solution Combinations
NCT00381446
Subjective Comparison of Pre-Lens Tear Film Stability With Daily Disposable Contact Lenses
NCT01839318
Quantitative Study of New Limbal Ring Prototypes
NCT02173535
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
etafilcon A/2-HEMA, EGDMA/hefilcon A
Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the etafilcon A lens first, the 2-HEMA, EGDMA Non-ionic material lens second and the hefilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
etafilcon A
Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
2-HEMA, EGDMA Non-ionic
Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
hefilcon A
Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
etafilcon A/hefilcon A/2-HEMA, EGDMA Non-ionic
Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the etafilcon A lens first, the hefilcon A lens second and the 2-HEMA, EGDMA Non-ionic material lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
etafilcon A
Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
2-HEMA, EGDMA Non-ionic
Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
hefilcon A
Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
2-HEMA, EGDMA Non-ionic/etafilcon A/hefilcon A
Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the 2-HEMA, EGDMA Non-ionic material lens first, the etafilcon A lens second and the hefilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
etafilcon A
Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
2-HEMA, EGDMA Non-ionic
Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
hefilcon A
Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
2-HEMA, EGDMA Non-ionic/hefilcon A/etafilcon A
Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the 2-HEMA, EGDMA Non-ionic material lens first, the hefilcon A lens second and the etafilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
etafilcon A
Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
2-HEMA, EGDMA Non-ionic
Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
hefilcon A
Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
hefilcon A/2-HEMA, EGDMA Non-ionic/etafilcon A
Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the hefilcon A lens first, the 2-HEMA, EGDMA Non-ionic material lens second and the etafilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
etafilcon A
Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
2-HEMA, EGDMA Non-ionic
Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
hefilcon A
Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
hefilcon A/etafilcon A /2-HEMA, EGDMA Non-ionic
Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the hefilcon A lens first, the etafilcon A lens second and the 2-HEMA, EGDMA Non-ionic material lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
etafilcon A
Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
2-HEMA, EGDMA Non-ionic
Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
hefilcon A
Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
etafilcon A
Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
2-HEMA, EGDMA Non-ionic
Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
hefilcon A
Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Fluency in English and ability to read and understand written English.
3. The subject must be able and willing to adhere to the instructions set forth in this clinical protocol.
4. The subject must be between 18 and 35 years of age.
5. The subject must be an adapted (minimum of 4 week history of daily wear prior to the baseline study visit) soft contact lens wearer in both eyes.
6. The subject must be East or Southeast Asia descent, e.g. ethnic Chinese, Japanese, Korean, Malay, Vietnamese, Indonesian, Filipino, etc. by self-report.
7. The subject must come in with a current (no more than 12 month old) spectacle or contact lens prescription as indicated. (NB: Emmetropic subjects who wear contact lenses for enhancement purposes only will also require a current contact lens prescription).
8. The subject's vertex corrected spherical equivalent distance refraction must be in the range of PLANO to -6.00 Diopter (D) in each eye.
9. The subject must have best corrected visual acuity on +0.24 logMAR (equivalent to 20/30 (-2)) or better in each eye.
10. The subject must own a wearable pair of spectacles (as indicated by current prescription) and wear them to all visits including the screening visit as required for vision correction. They must be willing to wear their spectacles during the 24 hour washout period leading up to each treatment visit (NB: Emmetropic subjects who do not own spectacles must agree to no lens wear on all visit days including the screening visit).
11. The subject must have normal eye (i.e., no ocular medications or infections of any type).
Exclusion Criteria
2. Have any ocular or systemic allergies or diseases that may interfere with contact lens wear.
3. Have any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but may not be limited to diabetes, hyperthyroidism, recurrent herpes simplex/zoster, Sjogren's syndromes, xerophthalmia, acne rosacea, Stevens-Johnson syndromes.
4. Use any topical medication such as eye drops or ointment.
5. Have entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, or aphakia.
6. Had any previous, or have planned, ocular or intraocular surgery (e.g., cataract surgery, radial keratotomy, photorefractive keratectomy (PRK), laser-assisted in situ keratomileusis (LASIK).
7. Have any grade 3.0 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the Efron classification scale or any other ocular abnormality that may contraindicate contact lens wear.
8. Have any known hypersensitivity or allergic reaction to contact lenses (as assessed by ocular history).
9. Have any ocular infection.
10. Have any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
11. Have participated in any contact lens or lens care product clinical trial within 14 days prior to study enrollment.
12. Have any infectious disease (e.g., hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g. HIV), by self-report.
13. Currently wear their contact lenes on an extended wear basis.
14. Is an employee of the investigational clinic (e.g., Investigator, Coordinator, Technician).
15. Currently wears toric or multifocal contact lenses. If the subject wears soft contact lenses for monovision, they must be willing to wear distance only correction in both eyes for the study.
18 Years
35 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Johnson & Johnson Vision Care, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hong Kong Polytechnic University
Hong Hom, Kowloon, Hong Kong
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CR-5360
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.